Massive (Life-Threatening) Hemoptysis

Overview

There is no universally accepted single threshold for massive or life-threatening hemoptysis; volumes ranging from 100 mL to 1000 mL in 24 hours have been used in the literature, and the classical criterion is 600 mL in 24 hours or 200 mL in a single episode of bleeding. The European Society of Interventional Radiology's bronchial artery embolization practice standards (CIRSE, 2022) define life-threatening hemoptysis as bleeding exceeding 100 mL in 24 hours, or respiratory failure requiring intubation (oxygen saturation below 60%), or bleeding causing hemodynamic instability; the Society of Chest Imaging and Interventions (SCII) consensus uses thresholds of 150 mL in 24 hours or 100 mL per hour.

Due to these threshold differences, the current approach uses PHYSIOLOGICAL EFFECT (hypoxemia, respiratory failure, hemodynamic deterioration) as the criterion rather than absolute volume; since the anatomical dead space of conductive airways is only about 150 mL, even a relatively small volume can fill the airways and cause suffocation, and in patients with low cardiopulmonary reserve, bleeding as little as 50 mL can be fatal. The main cause of death is not shock due to blood loss, but asphyxia caused by blood filling the alveoli; therefore, the priority is always the protection of the airway and gas exchange.

About 90% of the bleeding originates from high-pressure systemic bronchial arteries; only about 5% comes from the low-pressure pulmonary circulation, and another 5% comes from non-bronchial systemic collateral arteries. The pathophysiological chain is mostly chronic inflammation: in the setting of bronchiectasis, active or sequelae tuberculosis, and aspergilloma, bronchial arteries undergo hypertrophy, tortuosity, and neovascularization; these fragile vessels rupture under aortic pressure, leading to massive bleeding.

Pseudoaneurysmal dilation of the pulmonary artery wall in a tuberculosis cavity (Rasmussen aneurysm) is a classic example of massive hemoptysis of pulmonary origin. In developed countries, about 80% of cases are caused by lung cancer, active tuberculosis and its sequelae, bronchiectasis, and aspergillosis; in countries like Turkey, where tuberculosis is still seen (incidence approximately 13 per one hundred point zero zero zero according to the Ministry of Health), active tuberculosis and its sequelae (bronchiectasis, aspergilloma, Rasmussen aneurysm) are among the leading causes.

Despite extensive examination, about 5-34% of cases have no identifiable cause, and the condition is called cryptogenic hemoptysis. In diagnostic evaluation, contrast-enhanced multi-detector computed tomography (CT angiography) shows both the cause and site of bleeding in 82-100% of cases, is superior to bronchoscopy in identifying the cause (86% vs 70%; p=0.007), and maps target vessels for embolization; chest radiography identifies the bleeding site in 45-65% and the cause in 25-35% of cases, with about 10% of lung malignancies remaining hidden on X-ray and revealed on CT.

Bronchoscopy localizes the source in 73-93% of cases when performed during active bleeding or within 24-48 hours after the bleeding stops. Bronchial artery embolization (BAE) is the first-line treatment for definitive hemostasis; the mortality rate in severe cases is high with a conservative approach of observation and medication alone, whereas cohorts undergoing embolization have significantly lower hemoptysis-related mortality (0.8% vs 3.2% in a 2024 meta-analysis).

Key considerations

• Bronchiectasis (including cystic fibrosis) is among the most common causes of massive hemoptysis in patients with a history of chronic productive cough and recurrent respiratory tract infections; cylindrical or cystically dilated bronchi and hypertrophic bronchial arteries supplying them are seen on tomography.
• Active or previous tuberculosis presents with upper lobe cavitation, fibrosis, and traction bronchiectasis; pulmonary artery pseudoaneurysm (Rasmussen aneurysm) in the cavity wall can lead to massive bleeding of pulmonary origin that is resistant to bronchial artery embolization.
• Bronchial carcinoma and endobronchial metastases are distinguished by a history of smoking, weight loss, and masses on imaging; central tumors cause vessel invasion, resulting in recurrent hemorrhage that is more resistant to embolization.
• Aspergilloma (mycetoma) is recognized within a pre-existing cavity by a fungus ball that changes position and the surrounding air crescent sign; it bleeds heavily from hypertrophic bronchial arteries, and the recurrence rate after embolization is high.
• Pulmonary vasculitis and diffuse alveolar hemorrhage (ANCA-associated vasculitis, anti-glomerular basement membrane/Goodpasture’s disease, systemic lupus) are distinguished by diffuse, not focal, ground-glass infiltrates, dropping hemoglobin, and often renal involvement; since the bleeding originates not from a single artery but from alveolar-capillary membranes, embolization is ineffective, and treatment involves high-dose steroids and immunosuppression.
• Pulmonary embolism and infarction present with pleuritic chest pain, sudden shortness of breath, and generally small amounts of hemoptysis; left heart failure and mitral stenosis can mimic this presentation with pink frothy sputum, orthopnea, and murmur, but true massive bleeding in these cases is rare.
• Iatrogenic and traumatic causes include transbronchial biopsy (significant bleeding in about 2.8% of cases), rupture of the pulmonary artery by a Swan-Ganz catheter, and blunt or penetrating chest trauma; pulmonary artery rupture due to Swan-Ganz is a fatal condition requiring emergency intervention.
• Aortobronchial or broncho-vascular fistula presents with sudden massive hemoptysis after intermittent sentinel bleeding in patients with a history of aortic aneurysm or graft, and requires emergency vascular surgery or endovascular repair.
• Pseudopheumoptysis (pseudohemoptysis) is the coughing up of blood originating from the upper respiratory tract (nose-nasopharynx) or gastrointestinal system; hematemesis with a coffee-ground appearance along with nausea and vomiting or a history of nosebleeds suggests a nasopharyngeal source.

Why it matters

The priority order is based on pathophysiology: in massive hemoptysis, the patient generally survives as long as they can clear the blood by coughing; the main threat is blood entering the healthy lung and impairing gas exchange. Therefore, placing the bleeding side in a lower lateral decubitus position and protecting the airway comes before measuring the amount of bleeding and trying to stop it.

When intubation is required, a large-diameter (internal diameter 8.5-9 mm) single-lumen tube is preferred because this tube allows both the passage of a therapeutic flexible bronchoscope and a bronchial blocker. A double-lumen tube is not recommended in emergency settings: the lumens are narrow and easily blocked by clots, placement requires experience, and approximately 38% of attempts by anesthesiologists with limited thoracic experience fail; instead, selective intubation of the healthy main bronchus with a standard tube is a safer alternative.

Since most bleeding comes from high-pressure bronchial arteries, bronchial artery embolization (BAE) is the first-line definitive treatment; its technical success rate is 90-100%, and clinical success within the first 24 hours is 82-100%. The CIRSE 2022 practice standards recommend non-spherical polyvinyl alcohol (PVA) particles with a diameter of 355-500 microns as the embolic agent and PROHIBIT particles smaller than 300 microns due to the risk of tissue ischemia and necrosis; proximal coil embolization is generally not recommended because when collaterals develop, it prevents re-entry into the artery and makes possible second embolization impossible (coils are used only for pseudoaneurysms, large shunts, or to preserve spinal branches).

Since the main cause of recurrence is non-bronchial systemic collaterals, the guideline emphasizes searching for and embolizing these collaterals as much as possible during the first procedure. This advantage is supported by non-randomized but pooled evidence: a 2024 systematic review and meta-analysis (BMC Pulm Med, 5-8 cohorts, ~500-900 patients) comparing with conservative treatment showed that embolization reduces hemoptysis-related death (0.8% vs.

3.2%; odds ratio 0.20) and decreases recurrent bleeding (26.5% vs. 34.6%; odds ratio 0.37).

Surgical mortality is high in emergency situations (20-40%) and is therefore reserved for selected and localized cases. Tranexamic acid is an antifibrinolytic ADJUVANT:

A Cochrane review (Prutsky, 2016) found only two randomized trials and reported that the evidence is insufficient to judge the use of antifibrinolytics, although limited data may shorten bleeding duration; a 2020 meta-analysis found no significant difference in bleeding duration or resolution of hemoptysis in four randomized trials. The randomized data for nebulized tranexamic acid (Wand, 2018) is for NON-MASSIVE hemoptysis; in life-threatening cases, tranexamic acid alone is insufficient and should NOT DELAY embolization or bronchoscopy.

Correction of coagulopathy (platelet >50,000/µL, fibrinogen >150 mg/dL) and reversal of anticoagulation support bleeding control. Endobronchial temporary measures (cold saline lavage, topical adrenaline, endobronchial blocker), except in iatrogenic pulmonary artery rupture, resistant aspergilloma, and chest trauma, are only bridge therapies and do not provide definitive hemostasis.

Critical complications

• Asphyxia, that is, suffocation by blood, is the most fatal complication of massive hemoptysis; it is recognized by stridor, a sensation of suffocation, agitation, cyanosis, and rapidly falling oxygen saturation. Management involves placing the bleeding side down, intubation with a large-diameter single-lumen tube, aggressive suction, and if necessary, selective intubation of the healthy main bronchus.
• Aspiration of blood into the healthy lung results in new infiltrates, worsening oxygenation, and subsequent aspiration pneumonia; keeping the bleeding side dependent (down), early airway isolation, and appropriate antibiotics in case of developing infection are used for management.
• Spinal cord ischemia and transverse myelitis due to bronchial artery embolization occur from unintended (nontarget) embolization to the arterial branches supplying the Adamkiewicz artery (usually T8-L1) or branches from the intercostobronchial trunk and are observed post-procedure with lower extremity weakness, sensory loss, and urinary retention. The frequency has decreased from around 6% in the past to below 1% today with superselective techniques and non-ionic contrast; prevention relies on careful evaluation of pre-procedure angiography.
• Post-embolization syndrome and unwanted embolization present as chest pain (in approximately 91% of cases), dysphagia, and fever; less frequently, they manifest as bronchial infarction, esophagobronchial fistula, myocardial infarction, ischemic colitis, and transient cortical blindness. Most findings are self-limiting and last up to 2 weeks; severe or persistent findings suggest unwanted embolization and require treatment targeted at the involved organ.
• Recurrent bleeding after embolization occurs in 10-57% of cases and appears as early recurrence within the first 30 days, and as late recurrence thereafter; the main predictors are aspergilloma, active or multi-drug resistant tuberculosis, lung cancer, the presence of non-bronchial systemic collaterals, and incomplete embolization. Management includes repeat embolization, investigation of missed pulmonary artery sources, or surgery in selected cases.
• If bleeding continues despite technical success of embolization, a pulmonary artery source (pseudoaneurysm or shunt through bronchial arteries) may have been missed; in resistant cases where active extravasation is not seen on bronchial angiography, selective pulmonary angiography can establish the diagnosis, and embolization via the pulmonary artery approach is required.
• Emergency surgical resection is applied in localized disease where embolization has failed or cannot be performed, but emergency mortality reaches 20-40%; if possible, bleeding should first be controlled by BAE and surgery should be deferred to the elective period (mortality approximately 4-18%).

Special considerations

• The most common causes in pregnancy are similar to those in non-pregnant patients (tuberculosis reactivation, bronchiectasis, aspergilloma); for diagnosis, CT angiography and for treatment, bronchial artery embolization can be performed using abdominal lead shielding and is preferred over surgery that risks the fetus. In massive hemorrhage, the life of the mother takes priority and embolization should not be delayed.
• In young patients with cystic fibrosis, massive hemoptysis is the most common cause. The Cystic Fibrosis Foundation 2010 guideline does not recommend bronchoscopy before BAE in massive bleeding (it delays definitive treatment), recommends temporary suspension of all airway clearance therapies and noninvasive ventilation (BiPAP), and stopping nonsteroidal anti-inflammatory drugs for at least 5 mL of bleeding; in these patients, BAE stops bleeding in approximately 96% of cases within the first 24 hours.
• Unlike in adults, the most common cause in pediatrics is lower respiratory tract infection; the second in frequency is FOREIGN BODY ASPIRATION, which is suspected with sudden coughing fits, unexplained unilateral wheezing, and a history of choking, and is removed by rigid bronchoscopy. Bronchiectasis due to cystic fibrosis and congenital heart and vascular anomalies are also prioritized in the differential diagnosis.
• In immunosuppressed patients (neutropenia, organ transplant, advanced HIV infection), angioinvasive pulmonary aspergillosis and mucormycosis can erode the pulmonary vessel wall, causing pseudoaneurysms and massive hemorrhage; the risk of tuberculosis reactivation also increases. In these patients, antifungal and antituberculosis treatments are an integral part of bleeding control, and accompanying thrombocytopenia/coagulopathy should be corrected simultaneously.
• In the context of diffuse alveolar hemorrhage (ANCA-associated vasculitis, Goodpasture disease, lupus), since the bleeding originates not from a single artery but from widespread alveolar-capillary damage, bronchial artery embolization is USELESS; treatment consists of immunosuppression with high-dose corticosteroids, cyclophosphamide, or rituximab, and plasmapheresis in severe cases. Diagnosis is confirmed with increasingly hemorrhagic fluid during bronchoalveolar lavage, and infection must be excluded.
• In patients using anticoagulants or antiplatelets, or those with coagulopathy or liver failure, the bleeding threshold is lowered and severity increases; the target is platelet >50,000/µL and fibrinogen >150 mg/dL. Warfarin is reversed with vitamin K and prothrombin complex concentrate (PCC), and direct oral anticoagulants are reversed with a specific antidote. In liver failure, factor deficiencies and thrombocytopenia must be corrected together.
• Elderly patients usually carry a burden of comorbidities (coronary artery disease, chronic obstructive pulmonary disease, renal failure) and cannot safely tolerate emergency surgical resection; thus, in this group, bronchial artery embolization becomes a relatively more suitable option compared to surgery. Age alone is not a reason to delay embolization, and the decision should be based on the underlying functional reserve.
• In obese patients, the neck is short and thick, the larynx is displaced forward and upward, the pharyngeal and soft palate tissue are increased, and the tongue is enlarged; these features significantly increase the likelihood of a difficult airway in an environment where vision is already limited by bleeding. Therefore, early, prepared intubation (with a backup video laryngoscope, wide-bore suction catheter, surgical airway preparation) should be preferred in obese patients, and the procedure should be performed before vision is lost.

Follow-up plan

After bleeding is controlled, the underlying cause should be clarified: it is investigated with CT angiography, bronchoscopy, and etiology-specific tests (tuberculosis with acid-fast bacilli and culture, malignancy with cytology or biopsy, vasculitis with ANCA and anti-glomerular basement membrane antibodies, aspergillosis with galactomannan and serology), and cause-specific treatment (anti-tuberculosis, antifungal, immunosuppression, oncological guidance) is started; because embolization stops the bleeding but does not treat the underlying disease, and inadequate treatment is the main cause of recurrence. The patient is monitored in the intensive care unit or ward for early and late recurrence after embolization; recurrence occurs in 10-57% of cases, mostly within the first 30 days.

In early recurrence, repeat embolization, investigation of the overlooked pulmonary artery source, or surgical evaluation in selected cases is considered. Discharge depends on a secured airway, stable oxygenation, cessation of bleeding for at least 24-48 hours, and the initiation of cause-specific treatment.

The patient is given return warnings: in case of coughing up blood again, increasing shortness of breath, chest pain, fever, or dizziness and fainting, they should immediately go to the emergency room; weakness in the legs or urinary retention after embolization requires urgent evaluation as it may indicate spinal cord ischemia. The indication for anticoagulant and antiplatelet therapy is re-evaluated in a multidisciplinary manner; cause-specific treatment, smoking cessation, and, if needed, pulmonary rehabilitation are planned.

In centers without access to massive hemoptysis management (BAE, interventional radiology, thoracic surgery), an early referral chain should be established for these cases.